Pharmanutra (BIT:PHN) sets the stage with FY 2025 earnings

Pharmanutra (BIT:PHN) has just closed out FY 2025 with fourth quarter revenue of €39.0 million and net income of €6.0 million. This caps a trailing twelve month revenue line of €134.0 million and net income of €20.0 million that frames the latest set of results. The company has seen quarterly revenue move from €32.2 million in Q4 2024 to €39.0 million in Q4 2025, while trailing EPS across the last six quarters has ranged between €1.69 and €1.82. This gives investors a clearer view of the earnings base that underpins this report and the modestly higher profit margins being discussed.

See our full analysis for Pharmanutra.

With the headline numbers available, the next step is to compare them with the dominant narratives around Pharmanutra to see which stories the data supports and which ones appear less consistent with the reported figures.

Curious how numbers become stories that shape markets? Explore Community Narratives

20.4% earnings growth backs the growth story

• Over the last 12 months, Pharmanutra’s earnings grew 20.4% while revenue is forecast at about 12.3% per year and earnings at about 17% per year, both ahead of the Italian market forecasts of 5.7% for revenue and 9.8% for earnings.
• Bulls point to this faster growth profile as support for a growth narrative, and the trailing net margin of 14.9% versus 14.3% a year earlier fits that view, yet:
  • Trailing 12 month revenue of €133.968 million and net income of €20.002 million show that profitability is tied to a relatively concentrated revenue base, so future execution still matters.
  • The one year earnings growth of 20.4% compares with a five year average of 5.4% per year, which means investors may want to see whether this stronger phase is sustained before treating it as a new normal.

Margins and quarterly profit hold in the mid teens

• Pharmanutra reported trailing net profit margin of 14.9% on €133.968 million of revenue and €20.002 million of net income, while Q4 2025 net income of €5.993 million on €39.012 million of revenue sits in line with that mid teens margin range.
• What stands out for a bullish angle is that margin stability sits alongside growth, but the detailed quarterly pattern shows some variation that investors should be aware of:
  • Within FY 2025, quarterly net income moved between €2.436 million in Q1 and €6.749 million in Q2 on revenue between €26.822 million and €39.012 million, which means profitability is not a straight line even if the full year picture looks steady.
  • Compared with Q4 2024, where revenue was €32.195 million and net income was €3.439 million, the latest quarter’s higher profit level will likely be watched to see if it repeats across future periods rather than treating it as guaranteed.

Premium P/E and DCF gap frame valuation risk

• Pharmanutra’s trailing P/E of about 35.9x sits well above both the European Personal Products industry average of 16.6x and a peer average of about 20x, while the quoted DCF fair value of €57.73 is below the current share price of €74.8.
• Bears focus on this valuation gap and argue that growth expectations are already built in, and the numbers in the data give that concern some grounding:
  • The share price of €74.8 compared with the DCF fair value of €57.73 implies the stock trades above that modelled value, which can limit room for error if future earnings growth tracks closer to the forecast 17% rather than the recent 20.4%.
  • With a P/E roughly twice the 16.6x industry average, investors are paying a clear premium relative to peers at the same time as net margin sits in the mid teens at 14.9%, so the bearish view is that any slowdown in growth could weigh more heavily on sentiment.

On these numbers, skeptics may see Pharmanutra as a high expectation story rather than a clear bargain, so it can be useful to read how the cautious camp frames the risks before taking a view on the premium pricing. 🐻 Pharmanutra Bear Case

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Pharmanutra's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

With the mixed sentiment on growth and valuation in mind, it helps to move quickly, check the figures yourself and decide if the optimism around Pharmanutra fits your approach. To see what investors are excited about in these results, take a closer look at its 2 key rewards

See What Else Is Out There

Pharmanutra’s high P/E multiple relative to peers and the DCF fair value highlights that investors are paying a premium with limited room for error.

If that premium makes you uneasy, compare this setup with companies screened for quality at more appealing prices by checking out the 227 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.